세계 심낭염 치료제 시장 – 2024-2031년

Overview
The global pericarditis drugs market reached US$ 544.4 million in 2023 and is expected to reach US$ 816.6 million by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.
Pericarditis is swelling and irritation of the thin, saclike tissue surrounding the heart. This tissue is called the pericardium. Pericarditis often causes sharp chest pain. The chest pain occurs when the irritated layers of the pericardium rub against each other.
Pain from pericarditis is typically treated with over-the-counter pain relievers such as aspirin or ibuprofen (Advil, Motrin IB, and others). Colchicine (Colcrys, Mitigare) medication helps to reduce inflammation in the body and others. The market is driven by factors such as the rise in the prevalence of cardiovascular diseases and pericarditis and growing awareness & diagnosis regarding pericarditis.
Market Dynamics: Drivers
Rise in prevalence of cardiovascular diseases and pericarditis
The demand for the global pericarditis drugs market is driven by multiple factors. One of the primary factors is the rise in the prevalence of cardiovascular diseases and pericarditis.
According to WHO in 2024, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease, pericarditis, and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age.
Moreover, the rising prevalence of pericarditis cases would propel this market growth. According to a Mayo Clinic Proceedings article in May 2024, the incidence of acute pericarditis in the general population is estimated at approximately 27.7 cases per 100,000 subjects per year, whereas the standardized incidence rate of hospital admissions for pericarditis is 3.32 cases per 100,000 person-years.
In addition, major key players focus on research studies & developments and the rising number of clinical trials for the pericarditis drive the market growth. According to a Medical Dialogue news release in May 2024, a study called Variants at the interleukin-1 gene locus and pericarditis by deCODE genetics discovered sequence variants that are located in a genomic locus encoding interleukin-1 immune cytokines and are protective against pericarditis, offering valuable insights for future studies and the development of new treatment approaches.
Similarly, in April 2023, ScienceDirect research publication stated that the study by Wenguang Liu et al. proposed a combined strategy based on coadministration of lipo/pcircRNA and strontium ions-containing nanoparticles-encapsulated injectable hydrogel and nitric oxide (NO)-bearing liposome-loaded pericardial adhesive hydrogel patch for realizing intramyocardial gene/ion delivery and epicardial NO delivery to inhibit cardiomyocyte apoptosis and inflammatory response.
Also, in November 2023, R-Pharm International, LLC announced a clinical trial to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis.
Restraints
Factors such as the high cost of treatment, side effects associated with the drugs, limited availability of treatment options, stringent regulatory approvals, and the lesser number of approved drugs are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global pericarditis drugs market is segmented based on drug type, disease type, distribution channel, and region.
The NSAIDs segment accounted for approximately 58.5% of the global pericarditis drugs market share
The NSAIDs segment is expected to hold the largest market share over the forecast period. Nonsteroidal anti-inflammatory drugs (NSAIDs) are often the first-line treatment for pericarditis.
The adoption of dual therapy, which combines aspirin with colchicine, for the treatment of pericarditis is a significant driver for the pericarditis drugs market. Clinical trials have shown that combination therapy is more effective in reducing the relapse rate of pericarditis compared to conventional monotherapy.
According to NCBI studies, in September 2023, for acute and recurrent pericarditis, the combination of aspirin or other NSAIDs and colchicine is the recommended first-line treatment. This widespread adoption of NSAID-based dual therapy is driving the growth of the NSAIDs segment in the pericarditis drugs market.
Moreover, key players in the industry more focus on research studies, the rising number of clinical trials and product launches & approvals would propel this segment's growth of the market. For instance, in November 2022, Cardiol Therapeutics Inc. declared positive results demonstrating the protective effects of CardiolRx. It significantly reduces pericardial effusion and thickening of the pericardium.
Similarly, in January 2023, Cardiol Therapeutics Inc. announced that the first patient has been enrolled in the Company-sponsored Phase II open-label pilot study (NCT05494788) investigating the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis.
Also, in May 2022, Cardiol Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) had approved the Company's Investigational New Drug Application (IND) to begin a Phase II open-label pilot study to evaluate the tolerance and safety of CardiolRx, a pharmaceutically manufactured oral cannabidiol drug formulation, in patients with recurrent pericarditis.
Geographical Analysis
North America accounted for approximately 42.3% of the global pericarditis drugs market share
North America region is expected to hold the largest market share over the forecast period owing to the high prevalence of cardiovascular disease, increased awareness and diagnosis drive this market growth in this region.
According to CDC data in May 2024, in the U.S. heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. One person dies every 33 seconds from cardiovascular disease. About 695,000 people died from heart disease in 2021—that's 1 in every 5 deaths. About 40,000 people in the United States experience recurrent pericarditis, or inflammation of the sac-like structure that protects the heart, which can cause chest pain and may lead to fluid buildup around the heart muscle.
Moreover, a major number of key player's presence, a well-advanced healthcare system, and product launches & approvals would propel this market growth. For instance, in February 2024, Cardiol Therapeutics Inc. announced that the United States Food and Drug Administration has granted an Orphan Drug Designation for the Company’s lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx is currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis.
Also, in July 2023, The Food and Drug Administration (FDA) approved the first-ever anti-inflammatory drug LODOCO (colchicine, 0.5mg), for cardiovascular disease, the approved medication has been shown to reduce cardiac event risk in adults with atherosclerotic cardiovascular disease (ASCVD) or with multiple risk factors for cardiovascular disease by an additional 31% compared to standard-of-care treatment.
Market Segmentation
By Drug Tye
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Colchicine
• Others
By Disease Type
• Acute Pericarditis
• Chronic Pericarditis
• Recurrent Pericarditis
• Idiopathic Pericarditis
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the pericarditis drugs market include Kiniksa Pharmaceuticals, Cardiol Therapeutics, Bayer AG, Haleon group of companies, Johnson & Johnson Services, Inc., Hikma Pharmaceuticals USA Inc., Pfizer Inc., Catalent, Inc., Airgas, Inc and Takeda Pharmaceutical Company Limited among others.
Key Developments
 In June 2024, Kiniksa Pharmaceuticals, Ltd announced a partnership with National Hockey League (NHL) Hall-of-Famer, Henrik Lundqvist, to raise awareness in support of patients suffering from recurrent pericarditis. Lundqvist has faced the challenges of living with this painful and debilitating chronic autoinflammatory cardiovascular disease.
 In February 2022, Kiniksa Pharmaceuticals, Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. announced a strategic collaboration to develop and commercialize Kiniksa’s ARCALYST and mavrilimumab in the Asia Pacific Region. ARCALYST was discovered by Regeneron and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, and cryopyrin-associated periodic syndromes (CAPS).
 In November 2022, the US Food and Drug Administration (FDA) approved Rilonacept an interleukin (IL)-1 antagonist for the treatment of recurrent pericarditis.
 In April 2022, TGA released vaccine-related myocarditis severity details Fewer than 1% of all likely myocarditis or pericarditis cases linked to mRNA vaccines in Australia have been treated in intensive care.
Why Purchase the Report?
• To visualize the global pericarditis drugs market segmentation based on drug type, disease type, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global pericarditis drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global pericarditis drugs market report would provide approximately 62 tables, 54 figures, and 182 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies